GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baxalta Inc (NYSE:BXLT) » Definitions » Net Issuance of Debt

Baxalta (Baxalta) Net Issuance of Debt : $5,241 Mil (TTM As of Mar. 2016)


View and export this data going back to 2015. Start your Free Trial

What is Baxalta Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Baxalta's net issuance of debt for the three months ended in Mar. 2016 was $300 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2016 was $5,241 Mil.


Baxalta Net Issuance of Debt Historical Data

The historical data trend for Baxalta's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxalta Net Issuance of Debt Chart

Baxalta Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Net Issuance of Debt
- - - 4,941.00

Baxalta Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 4,941.00 - - 300.00

Baxalta Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,241 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baxalta Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Baxalta's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxalta (Baxalta) Business Description

Traded in Other Exchanges
N/A
Address
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Executives
Gail D Fosler director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
John Glasspool officer: See Remarks C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Dagmar Rosa-bjorkeson officer: EVP and President, Biosimilars C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
David D. Meek officer: EVP and President, Oncology 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Peter G Edwards officer: SVP and General Counsel C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Robert J. Hombach officer: EVP. CFO and COO C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Blake E Devitt director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anne-marie Law officer: EVP & Head of Human Resources C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Gavin James R Iii director BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015
John D Forsyth director C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015
Ludwig Hantson director, officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921

Baxalta (Baxalta) Headlines

From GuruFocus

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 12-10-2015

Third Avenue Buys Baxter Spin-Off

By Kyle Ferguson Kyle Ferguson 01-17-2016

Baxalta Vs. AbbVie: Biopharma Spin-Off Battle

By Ben Reynolds Ben Reynolds 08-20-2015

Jeff Auxier Sells Precision Castparts, AT&T, Microsoft

By Tiziano Frateschi Tiziano Frateschi 06-23-2016

Third Avenue Management Comments on Baxalta

By Holly LaFon Holly LaFon 03-29-2016

Keeley Funds Comments on Baxalta Inc.

By Holly LaFon Holly LaFon 02-03-2016

Daniel Loeb Comments on Seven & i Holdings

By Holly LaFon 11-03-2015

Is Baxalta a Good Spin-Off Opportunity?

By Raman Minhas Raman Minhas 10-15-2015

Undervalued Baxalta Shares Target of Acquisition by Shire Plc

By Ben Reynolds Ben Reynolds 08-05-2015